Saturday 17 October 2026
Export ISPC’s income statement to Excel — free account
iSpecimen Inc.
ISPC Healthcare Diagnostics & Research
iSpecimen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 million, down 79.2% from fiscal 2024. In the quarter to June 2026, revenue fell 78.7%, EPS grew 94.2% and free cash flow fell 257.7%, each against the same quarter a year earlier.
0.92
0.11
−10.68%
Follow ISPC
iSpecimen Inc. (ISPC) P/E ratio
iSpecimen Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 2.9× (March 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 23 more quarters | Free account |
Against its own ten years
Low 0.0×
High 2.9×
Ten-year median
0.0×
Current reading's percentile
86
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| DMTKQ DermTech, Inc. compare | n/m |
| NOTVQ Inotiv, Inc. compare | n/m |
| TTOO T2 Biosystems, Inc. compare | n/m |
| XWEL XWELL, Inc. compare | n/m |
| PRPH ProPhase Labs, Inc. compare | n/m |
| ISPC iSpecimen Inc. | n/m |
| NDRA ENDRA Life Sciences Inc. compare | n/m |
| BIAF bioAffinity Technologies, Inc. compare | n/m |
| AWHL Aspira Women's Health Inc. compare | n/m |
| Diagnostics & Research industry median | 35.6× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)